Loading
Old version — revision 1
This is a fixed snapshot of Reproductive longevity, saved by Import as part of the initial corpus import. It is not edited and it is not updated; the article may have changed since.
Edit summary: Initial import of content/reproductive-longevity.md — the filesystem corpus, unchanged. Not an edit.
The functional lifespan of the reproductive system, and efforts to extend it in the ovary, which loses function decades before most other organs.
Reproductive longevity is the duration over which the reproductive system remains functional, and, as a research programme, the attempt to extend it. In women the relevant organ is the ovary, which loses most of its function around the age of 51 while the heart, liver, and brain are still decades from failure. That asymmetry makes the ovary the clearest example in human biology of an organ ageing on its own schedule, and it is why the field has become a testbed for the wider claims of the Geroscience hypothesis. The uterus is not the constraint: it can carry a pregnancy well after menopause when donated oocytes are used, and Uterus transplantation has produced live births in women who had no working one of their own.
The ovary declines along two axes that are often conflated.
Quantity. Germ cells reach their maximum number in mid-gestation, at several million, and fall continuously thereafter through atresia, a programmed loss largely independent of ovulation. By puberty a few hundred thousand primordial follicles remain; by menopause, a few hundred. Clinically this pool is estimated by anti-Müllerian hormone in blood and by antral follicle count on ultrasound, neither of which reliably predicts when an individual will reach menopause.
Quality. The proportion of eggs that segregate their chromosomes correctly falls steeply from the mid-thirties. The mechanistic explanation with the strongest support concerns cohesin, the protein complex that holds sister chromatids together. It is loaded onto chromosomes in fetal oocytes and is not appreciably replenished afterwards, so a woman's oocytes have been holding their chromosomes with the same molecules for decades by the time they are ovulated. Cohesion deteriorates, the meiotic spindle checkpoint is permissive in oocytes, and missegregation follows. Declining mitochondrial function in the oocyte, connected to the mechanisms in Mitochondrial dysfunction in aging, is a contributing but probably secondary factor.
The consequence is the age curve familiar from fertility clinics: the fraction of embryos that are euploid falls from a clear majority in the early thirties to a minority by the early forties, which is the dominant reason live-birth rates per cycle decline and the reason Embryo selection is used most in exactly the group where there are fewest embryos to select from.
Why this is a geroscience problem, not only a fertility problemEarlier menopause is associated with higher risk of cardiovascular disease, osteoporosis, and all-cause mortality, and surgical removal of the ovaries before natural menopause carries similar associations. In mice, transplanting young ovaries into old ovariectomised animals extended lifespan, suggesting the ovary is not merely an early casualty of ageing but a contributor to it.1 Whether the same causal arrow operates in humans is unresolved.
There is no consensus mechanism, but three explanations recur.
The first is the fixed pool: unlike blood, gut, or skin, the ovary has no renewing stem cell population that is generally accepted, so losses are permanent. Claims of oogonial stem cells in adult human ovaries have been made and remain disputed, with several laboratories unable to reproduce the key findings.
The second is DNA damage. Genome-wide association studies of age at natural menopause identify hundreds of loci enriched for genes in DNA damage response and repair pathways, and manipulating one of them, the checkpoint kinase CHEK2, extended reproductive lifespan in mice.2 Human carriers of loss-of-function variants in the same gene reach menopause later. This is one of the cleaner links from a genetic association to a candidate intervention anywhere in Hallmarks of aging research.
The third is evolutionary. Menopause is rare among mammals, documented in humans and in a handful of toothed whale species. The grandmother hypothesis holds that a post-reproductive phase was selected because assisting descendants outweighed continued childbearing; a competing account emphasises reproductive conflict between generations of females sharing a group. Both imply that the ovary's schedule is not simply a failure but a trait under selection, which complicates the assumption that extending it is straightforwardly beneficial.
Existing practice preserves gametes rather than extending the organ.
Oocyte cryopreservation. Vitrification made egg freezing viable, and professional bodies removed the experimental label from it in the 2010s. Outcomes depend heavily on the age at which eggs are frozen and on how many are stored; freezing at 38 buys much less than freezing at 30, and clinics vary widely in how clearly they communicate that.
Ovarian tissue cryopreservation. Strips of ovarian cortex are removed, frozen, and later grafted back, restoring both fertility and endocrine function for a period. Developed for patients facing gonadotoxic cancer treatment, it now has a substantial record of live births and is no longer classed as experimental by the main professional societies. Companies have marketed it to healthy women as a way to delay menopause, a use for which there is no controlled evidence and which the same societies have criticised.
Hormone therapy. Replacing oestrogen treats vasomotor symptoms and preserves bone density. It does not preserve the ovary, and the trial evidence on cardiovascular and mortality outcomes remains contested, with the timing of initiation relative to menopause the main variable in dispute. It is a treatment for consequences, not a geroprotector.
The candidate that has drawn most attention is Rapamycin. Inhibiting mTOR slows the activation of primordial follicles in mice, preserving the reserve. A small trial at Columbia University has tested low-dose weekly rapamycin in women in their late thirties and early forties with ovarian reserve and follicular decline as endpoints; preliminary reports have described a slower decline in the treated group. The study is small, short, and uses surrogate measures, and no result of this kind has yet been shown to translate into a later menopause or a live birth advantage.
Anti-Müllerian hormone is being developed from the other direction. It acts as a brake on primordial follicle recruitment, and sustained administration protects the reserve in animal models; at least one company is developing it as a therapeutic. Senolytic and NAD-raising approaches, discussed in Senolytics and NAD+ precursors, have shown effects on ovarian markers in rodents with no human ovarian data to speak of.
The area acquired dedicated funding in the late 2010s through a philanthropically supported consortium hosted at the Buck Institute for Research on Aging, which treats ovarian ageing as a research programme in its own right rather than a subfield of fertility medicine. That framing is itself the argument: reproductive ageing had previously been studied by clinicians trying to achieve pregnancies rather than by biologists trying to understand why one organ fails first.
The endpoint problemEvery intervention above is measured against surrogates: anti-Müllerian hormone, antral follicle count, oocyte yield. None of these has been validated as predicting the outcomes people care about, namely a healthy birth or a later menopause. This is the same obstacle described in Aging biomarkers and the same correlation-versus-causation trap that limits the Epigenetic clocks, and it is arguably more acute here because a definitive trial would have to run for a decade.
The bypass route is different in kind. In vitro gametogenesis would make eggs from somatic cells, decoupling the age of the gamete from the age of the ovary entirely. It would not address the endocrine consequences of ovarian failure, and it carries its own unresolved question about whether a gamete made from a fifty-year-old's cells inherits that person's accumulated mutations.
The male system declines more gradually and differently. Sperm production continues into old age, but semen parameters deteriorate slowly and the rate of de novo mutations transmitted to offspring rises with paternal age, by roughly one to two additional mutations per year of the father's age at conception.3 This contributes to a measurable increase in the risk of some neurodevelopmental conditions with older fathers, though the absolute risks remain small. There is no male equivalent of menopause and no clear analogue of the ovarian reserve, which is why the field is overwhelmingly focused on the ovary.
Whether ovarian ageing causes systemic ageing or merely precedes it is the central unresolved question, and it determines whether extending reproductive lifespan is a fertility intervention or a Healthspan intervention. The mouse transplant data point one way; the association between later menopause and higher rates of hormone-sensitive cancers points to a trade-off rather than a free gain.
A second question is whether the ovary is a good general model for organ-specific ageing. Its advantages are obvious: a clear functional endpoint, a measurable decline, a timescale short enough for trials, and a large motivated population. Its disadvantages are equally clear. The fixed-pool architecture is unusual, and an organ that runs down a non-renewable stock may say little about renewing tissues, whose failure looks more like Stem cell exhaustion or the accumulation described in Cellular senescence. If it does generalise, reproductive longevity becomes the first place a geroprotective drug could be shown to work in humans within a decade rather than a lifetime.
paperCargill, S. L. et al. "Age of ovary determines remaining life expectancy in old ovariectomized mice." Aging Cell, 2003. ↩
paperRuth, K. S. et al. "Genetic insights into biological mechanisms governing human ovarian ageing." Nature, 2021. ↩
paperKong, A. et al. "Rate of de novo mutations and the importance of father's age to disease risk." Nature, 2012. ↩